Abiopharma

Disclosure Of Interest/ Changes In Interest Of Substantial Shareholder(s)/ Unitholder(s) - Change In Interest - Lee Keck Keong

FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY HAS BEEN APPROVED TO RECEIVE SCOTT COUNTY OPIOID ABATEMENT FUNDS

New Form 8-K - CASSAVA SCIENCES INC Filed: 2025-06-30 AccNo: 0001171843-25-004211 Size: 231 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Celcuity Inc. Filed: 2025-06-30 AccNo: 0001641172-25-017043 Size: 278 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Celcuity Inc Notification (CELC)

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

New Form 8-K - INDIVIOR PLC Filed: 2025-06-30 AccNo: 0001625297-25-000046 Size: 159 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

A New Press Release from Oncolytics Biotech, Inc

Moderna - Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

Iterum Names Christine Coyne as Chief Commercial Officer to LeadORLYNVAH™ Launch and Commercial Growth